Investing in the Future: Apellis Pharmaceuticals' Key Events
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is gearing up for an exciting series of investor conferences that promise to shed light on the company's innovative approach to treating challenging diseases through complement science. As a global biopharmaceutical leader, Apellis is making strides with its newly developed therapies aimed at improving the lives of patients with serious medical conditions.
Upcoming Conferences to Note
The company has announced its participation in several key investor conferences, which will include interactive webcast fireside chats. Here are the details:
Citi's Global Healthcare Conference
Scheduled for December 2nd, this prestigious conference will commence at 2:30 PM ET. It is set to be an invaluable opportunity for Apellis to connect with investors and share insights into its latest advancements.
Evercore 8th Annual Healthcare Conference
On December 3rd, Apellis will again engage with investors at this conference, starting at 2:10 PM ET. These sessions will allow for an exchange of ideas and information on the company's promising developments.
Accessing the Webcasts
For those interested in following along, the live webcasts will be accessible on Apellis' website under the 'Investors and Media' section. Following the events, replays will be available for approximately 30 days, giving investors ample time to engage with the presentations.
Apellis Pharmaceuticals: A Transformational Journey
Apellis is making history by spearheading the complement medicine revolution, having introduced its first new class of therapies aimed at complement biology in over a decade. Currently, the company boasts two approved C3-targeting therapies intended to combat four significant diseases. Some notable advances include pioneering treatments for conditions like geographic atrophy, a major cause of blindness, and addressing severe kidney ailments that affect patients aged 12 and above.
The Future of Complement Science
Apellis Pharmaceuticals holds a strong conviction that the potential of C3-targeted therapies is just beginning to unfold. Their groundbreaking work in optimizing outcome-focused treatments signifies a promising horizon for patients suffering from a range of severe diseases. As the company continues to explore the benefits of complement targeting, advancements are expected to emerge, leading to further life-changing therapies.
Contact Information and Investor Queries
For further information, interested parties can reach out through Apellis' investor contact:
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
Frequently Asked Questions
What is the focus of the upcoming investor conferences?
The conferences will highlight connectivity between Apellis Pharmaceuticals and investors, focusing on the company’s recent advancements in complement science.
How can investors access the webcast?
The live webcasts will be available on Apellis' website in the 'Investors and Media' section, with replays accessible for 30 days after the events.
What is unique about Apellis Pharmaceuticals?
Apellis stands out as a leader in complement science, introducing the first new class of therapies that target the complement system in over 15 years.
What therapies has Apellis launched?
Apellis has launched two C3-targeting therapies that address serious diseases, including geographic atrophy and severe kidney conditions.
How can I contact Apellis for more information?
You can contact Eva Stroynowski via email at ir@apellis.com or by calling 617.938.6229 for investor inquiries.
